MonicaShawMD

Chief, Division of General Internal Medicine, Palliative Medicine and Medical Education at University of L

Dr. Shaw is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
201 Abraham Flexner Way
Louisville, KY 40202
Phone+1 502-589-6788

Fax+1 502-587-4146

University of Louisville School of MedicineResidency, Internal Medicine, 1992 - 1995
University of Louisville School of MedicineClass of 1992

PubMed

44 citations
Improving medical graduates' training in palliative care: advancing education and practice
Barbara Head, Tara Schapmire, Lori Earnshaw, John Chenault, Mark Pfeifer
Advances in Medical Education and Practice. 2016-02-24
30 citations
"I will never forget": what we learned from medical student reflections on a palliative care experience.
Barbara Head, Lori Earnshaw, Ruth B. Greenberg, Robert C. Morehead, Mark Pfeifer
Journal of Palliative Medicine. 2012-05-11
9 citations
Design and rationale of the medical students learning weight management counseling skills (MSWeight) group randomized controlled trial
Judith K. Ockene, Karen M. Ashe, Rashelle B. Hayes, Linda C. Churchill, Sybil L. Crawford
Contemporary Clinical Trials. 2018-01-01

$Bristol Myers Squibb’s Abecma (Idecabtagene Vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma$
Bristol Myers Squibb’s Abecma (Idecabtagene Vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple MyelomaMarch 21st, 2024
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (Luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)April 3rd, 2024